Our Products

THE COHERUS PIPELINE TARGETS ATTRACTIVE MARKETS

Our regulatory submission for our first product, CHS-1701 pegfilgrastim biosimilar, was accepted by both US and EU regulatory agencies in 2016. We are on track to filing two more applications in 2017.

Candidate Originator Product Originator Approved Indications Pre-Clinical Phase 1 Phase 31 Status Timing
Long Acting G-CSF Pipeline
Candidate Originator Product Originator Approved Indications Pre-Clinical Phase 1 Phase 31 Status Timing
CHS-1701 pegfilgrastim (Neulasta) Febrile neutropenia Arrow Right

BLA/MAA submitted

Region Targeted Filing
US Submitted
EU Submitted
Anti-TNF Pipeline
Candidate Originator Product Originator Approved Indications Pre-Clinical Phase 1 Phase 31 Status Timing
CHS-0214 etanercept (Enbrel) Ankylosing Spondylitis Juvenile Idiopathic Arthritis Psoriasis (PsO) Psoriatic Arthritis Rheumatoid Arthritis (RA) Arrow Right

Phase 3 clinical studies in psoriasis and RA underway

Region Targeted Filing
EU2 1H'17
CHS-1420 adalimumab (HUMIRA)

Ankylosing Spondylitis

Crohn's disease

Juvenile Idiopathic Arthritis

Psoriasis (PsO)

Psoriatic Arthritis

Rheumatoid Arthritis (RA)

Ulcerative Colitis

Hidradentis suppurativa Uveitis

Arrow Right

Phase 1 study complete Phase 3 clinical study in psoriasis underway

Region Targeted Filing
US 1H'17
EU 2017

1 Phase 3 or BLA-enabling study

2 The therapeutic protein in etanercept is subject to certain originator-controlled United States patents expiring in 2028 and 2029. Assuming these patents are valid and enforceable, and that we would be unable to obtain a license to them, we do not expect to commercialize CHS-0214 in the United States prior to their expiration